Stockreport

Syremis Therapeutics Launches with $165M to Develop Best-in-Class Medicines for Mental Health Conditions [Yahoo! Finance]

Bristol-Myers Squibb Company  (BMY) 
Last bristol-myers squibb company earnings: 2/6 07:05 am Check Earnings Report
US:NYSE Investor Relations: bms.com/investors.html
PDF Lead program ST-905, a potent M1/M4 muscarinic agonist, currently in Phase 1 clinical development Second program ST-901, a novel NMDA antagonist, currently in IND-ena [Read more]